Sensai
Reading the tape…Pulling live market data…Setting the scene…
Sensai
AI Stock Dissection
AI Stock Dissection
POLYMED
Mr. Himanshu Baid · New Delhi, India
₹1,678.50
▲+1.87%POLYMED is trading near its 52-week low with strong revenue growth but high valuation, reflecting market concerns about premium valuation despite solid healthcare fundamentals.
Exchange
NSI
Currency
INR
Day range
₹1,654.80 – ₹1,693.00
52-week range
₹1,182.00 – ₹2,144.90
Sector
Healthcare
Industry
Medical Instruments & Supplies
AI investment rating
AI analysis70% confidence
The stock appears overvalued at current levels with a P/E of 52.78, trading in the lower third of its 52-week range, suggesting limited upside in the near term despite strong fundamentals.
21.7% below the 1-year high · trend down
Hedge-fund memo
Today
Stock gained 1.87% but remains significantly below its 52-week high, indicating some recovery but still in value territory.
This week
No specific weekly trend provided, but trading near the lower end of recent range suggests ongoing caution.
This month
Trading below 52-week high suggests some correction over the past month despite sector strength.
Bull thesis
Bear thesis
Narrative read
Neutral
Composite sentiment
Institutional
Cautious due to low ownership
Retail
Mixed with some buying at lower levels
News flow
Limited analyst coverage creates information asymmetry
Read
Sentiment remains divided between growth prospects and valuation concerns
Live news feed unavailable right now — showing the AI's qualitative read instead. Not scraped platform data.
Smart money
Named holders aren't published for this listing (common for Indian stocks). The split at left is live.
Financial health
Profitability
Growth
Balance sheet
Financial statements
Earnings intelligence
Beat estimates in 1 of 4 recent quarters (EPS actual vs. consensus).
6.53 vs 7.975
-18.12% surprise
7.4764 vs 9.4
-20.46% surprise
9.06 vs 9.83333
-7.86% surprise
Competitive landscape
| Company | Market cap | P/E | ROE | Op. margin | Rev. growth |
|---|---|---|---|---|---|
| POLYMED | 170.33B | 52.78 | 10.85% | 13.50% | 21.30% |
| JBCHEPHARM | 387.93B | 54.22 | 18.69% | 16.48% | -4.80% |
| NH | 422.51B | 52.06 |
Technical intelligence
Volume
RSI (14) · 70 overbought / 30 oversold
MACD (12,26,9) · MACD vs signal
Candlesticks, volume, RSI and MACD from 500sessions of real Yahoo daily data. Moving averages use full history, so they're accurate at the left edge. Support / resistance are the 52-week low / high. Educational — technical signals are not buy or sell calls.
Risk intelligence
High valuation pressure
Mitigation: Demonstrate consistent growth to justify premium multiple
Regulatory changes in healthcare sector
Mitigation: Diversify product portfolio to adapt to changing regulations
Business intelligence
Competitive moat
Established distribution network and brand recognition in the medical supplies sector provides competitive advantage.
Supply chain
Upstream (inputs / suppliers)
↓
Downstream (customers / markets)
M&A / strategic moves
Catalyst calendar
Earnings report
Potential expansion in new markets
Thesis builder
Bull case
Strong revenue growth and healthy margins could drive re-rating if valuation normalizes
Base case
Consistent growth in medical supplies sector maintains stable performance
Bear case
High valuation could lead to correction if growth slows or market sentiment turns negative
Time horizon
12-18 months
Est. CAGR
15-20%
Entry (qual.)
Wait for price correction below 1500 INR
Exit (qual.)
Consider profit booking above 2000 INR
Overall conviction 70%
Knowledge graph
Executives & sector are live; peers are clickable → their dissection. Institutional holders shown where the exchange publishes them.
Portfolio impact
Enter tickers + weights, then see how POLYMED fits.
Scenario simulator
Simulate a macro shock and see the illustrative impact:
Tailwind for tech & enablers.
Illustrative impact
Medium prob.Directional illustration only — not modelled on this company's actuals. A real simulator needs company financials.
Explain like…
Re-explain POLYMED for a different audience:
Pick a persona to get a tailored explanation.
Sensai publishes educational market commentary, not investment advice. We are not SEBI-registered investment advisers or research analysts, and nothing here is a recommendation to buy, sell, or hold any security.
Live prices, index levels, and other market data are pulled from third-party feeds, may be delayed, and can be inaccurate or unavailable. Do not rely on them for trading decisions.
Investing in equities carries risk, including the loss of principal. Always do your own research and consider consulting a SEBI-registered adviser before making any investment decision.
Hidden risks
Hidden opportunities
Watch next
Hold position with cautious optimism given strong growth metrics but elevated valuation.
Annual income statement, oldest → newest. Live via Yahoo.
9.17 vs 8.7
5.40% surprise
| 19.84% |
| 13.72% |
| 75.80% |
| SYNGENE | 160.68B | 72.45 | — | 3.90% | -15.80% |
Peers via Yahoo's similarity graph, same-sector first; fundamentals live. Ask the AI copilot below for a qualitative head-to-head.
Support (day/52w low)
₹1,654.80
Resistance (day/52w high)
₹1,693.00
Volume
36,747
Trend
down
RSI (14)
54
MACD
bearish
MA cross
death
50-day MA
₹1,570.41
200-day MA
₹1,597.15
vs 200-DMA
5.1%
RSI/MACD computed from 6 months of daily closes; moving averages from Yahoo. Options positioning still needs an options feed.